Source Agriculture Corp., an agtech investment company, is investing in Ascribe Bioscience, a company founded in 2017 based on discoveries at the Boyce Thompson Institute at Cornell University.

Ascribe is focused on discovering natural products derived from the soil microbiome. The company’s lead product, Phytalix, is based on naturally occurring molecules produced by soil organisms, controlling a broad spectrum of pathogens across multiple crops, including corn, wheat, soy, rice, potatoes, and tomatoes.

Phytalix works by triggering the plant’s immune system, allowing crops to respond more rapidly to stressors such as pathogens. Applied as either a seed treatment or foliar spray, the product requires only small amounts of active ingredient per acre.
‍
Ascribe says its proprietary platform uses advanced metabolomics to unlock the potential of the soil microbiome, identifying small molecules that enhance plant health and productivity.
‍
“We believe that Ascribe Bioscience’s approach represents the future of sustainable crop protection,” said Aman Gill, president and CEO of Source Agriculture Corp. “Their innovative platform and commitment to natural, effective solutions align perfectly with Source Agriculture’s mission to support technologies that not only improve farming productivity but also contribute to environmental sustainability. Our investment in Ascribe is a testament to our confidence in their ability to deliver impactful, science-driven solutions for farmers around the world.”
‍
The value of the investment was not disclosed.